Enzymotec Ltd. Announces "New Food Raw Material" Certification for K-REAL(R) Krill Oil in China
08 January 2014 - 8:05AM
Enzymotec Ltd. (Nasdaq:ENZY), a developer, manufacturer and
marketer of innovative bio-active lipid ingredients, announced
today its K-REAL® krill oil has received "New Food Raw Material"
certification in China.
"We are excited to achieve this important milestone in China for
our K-REAL® krill oil," said Dr. Ariel Katz, President and Chief
Executive Officer of Enzymotec Ltd. "This certification further
illustrates our scientific and product safety commitment to
consumers. We believe that China will continue to represent a
tremendous growth opportunity for us with a vast portion of the
population increasingly consuming premium health and wellness
products."
K-REAL® is one of Enzymotec's line of premium omega-3 products,
extracted from sustainable Antarctic krill using a unique
proprietary extraction process called MSO®. K-REAL® is comprised of
naturally occurring phospholipids and triglycerides bound to EPA
and DHA, and the powerful antioxidant astaxanthin. K-REAL® has been
clinically proven to be significantly more effective than fish oil
in increasing the omega-3 index.
About Enzymotec Ltd.
Enzymotec is a leading global supplier of specialty lipid-based
products and solutions. The Company develops, manufactures and
markets innovative bio-functional lipid ingredients, as well as
final products, based on sophisticated processes and
technologies.
Forward Looking Statements
This release may contain forward-looking statements, which
express the current beliefs and expectations of Company management.
Such statements involve a number of known and unknown risks and
uncertainties that could cause our future results, performance or
achievements to differ significantly from the results, performance
or achievements expressed or implied by such forward-looking
statements. Important factors that could cause or contribute to
such differences the following risks: a high proportion of the
sales of our InFat product is sold to end users by a single company
in China; we rely on our Swedish joint venture partner to
manufacture InFat, and certain matters related to the joint venture
are or, based on communications from our joint venture partner, are
the subject of disagreement; our gross profits may be adversely
affected if we are only able to obtain lower quality krill meal;
our ability to obtain krill may be affected by conservation
regulation or initiatives; we are dependent on a single facility
that houses the majority of our operations; we may not be able to
expand our production or processing capabilities or satisfy growing
demand; our product development cycle is lengthy and uncertain, and
our development or commercialization efforts for our products may
be unsuccessful; we are subject to significant and increasing
government regulations regarding the sale and marketing of our
products; we may not be able to protect our proprietary technology
or prevent its unauthorized use by third parties; we are currently
subject to litigation, and in the future may become subject to
additional litigation, regarding intellectual property rights; and
other factors discussed under the heading "Risk Factors" in the
Company's final prospectus for its initial public offering filed
with the Securities and Exchange Commission on September 30, 2013.
Forward-looking statements in this release are made pursuant to the
safe harbor provisions contained in the Private Securities
Litigation Reform Act of 1995. These forward-looking statements are
made only as of the date hereof, and the company undertakes no
obligation to update or revise the forward-looking statements,
whether as a result of new information, future events or
otherwise.
CONTACT: ICR, LLC
Katie Turner
646-277-1228
Katie.turner@icrinc.com
-or-
John Mills
310-954-1105
John.mills@icrinc.com
ENZYMOTEC LTD. (NASDAQ:ENZY)
Historical Stock Chart
From Jun 2024 to Jul 2024
ENZYMOTEC LTD. (NASDAQ:ENZY)
Historical Stock Chart
From Jul 2023 to Jul 2024